127 related articles for article (PubMed ID: 7698238)
1. A cell-specific and selective effect on transactivation by the androgen receptor.
Gordon DA; Chamberlain NL; Flomerfelt FA; Miesfeld RL
Exp Cell Res; 1995 Apr; 217(2):368-77. PubMed ID: 7698238
[TBL] [Abstract][Full Text] [Related]
2. Novel steroid receptor phyto-modulator compound a inhibits growth and survival of prostate cancer cells.
Yemelyanov A; Czwornog J; Gera L; Joshi S; Chatterton RT; Budunova I
Cancer Res; 2008 Jun; 68(12):4763-73. PubMed ID: 18559523
[TBL] [Abstract][Full Text] [Related]
3. Sterol regulatory element-binding protein-1c represses the transactivation of androgen receptor and androgen-dependent growth of prostatic cells.
Suh JH; Gong EY; Kim JB; Lee IK; Choi HS; Lee K
Mol Cancer Res; 2008 Feb; 6(2):314-24. PubMed ID: 18245227
[TBL] [Abstract][Full Text] [Related]
4. Transcriptional regulation of the androgen signaling pathway by the Wilms' tumor suppressor gene WT1.
Zaia A; Fraizer GC; Piantanelli L; Saunders GF
Anticancer Res; 2001; 21(1A):1-10. PubMed ID: 11299720
[TBL] [Abstract][Full Text] [Related]
5. The androgen receptor (AR) amino-terminus imposes androgen-specific regulation of AR gene expression via an exonic enhancer.
Grad JM; Lyons LS; Robins DM; Burnstein KL
Endocrinology; 2001 Mar; 142(3):1107-16. PubMed ID: 11181525
[TBL] [Abstract][Full Text] [Related]
6. c-Jun has multiple enhancing activities in the novel cross talk between the androgen receptor and Ets variant gene 1 in prostate cancer.
Cai C; Hsieh CL; Shemshedini L
Mol Cancer Res; 2007 Jul; 5(7):725-35. PubMed ID: 17634427
[TBL] [Abstract][Full Text] [Related]
7. Occupancy and composition of proteins bound to the AP-1 sites in the glucocorticoid receptor and c-jun promoters after glucocorticoid treatment and in different cell types.
Barrett TJ; Vedeckis WV
Recept Signal Transduct; 1996; 6(3-4):179-93. PubMed ID: 9259052
[TBL] [Abstract][Full Text] [Related]
8. Ectopic expression of the amino-terminal peptide of androgen receptor leads to androgen receptor dysfunction and inhibition of androgen receptor-mediated prostate cancer growth.
Minamiguchi K; Kawada M; Ohba S; Takamoto K; Ishizuka M
Mol Cell Endocrinol; 2004 Feb; 214(1-2):175-87. PubMed ID: 15062556
[TBL] [Abstract][Full Text] [Related]
9. c-Jun enhancement of androgen receptor transactivation is associated with prostate cancer cell proliferation.
Chen SY; Cai C; Fisher CJ; Zheng Z; Omwancha J; Hsieh CL; Shemshedini L
Oncogene; 2006 Nov; 25(54):7212-23. PubMed ID: 16732317
[TBL] [Abstract][Full Text] [Related]
10. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
[TBL] [Abstract][Full Text] [Related]
11. Isolation and identification of L-dopa decarboxylase as a protein that binds to and enhances transcriptional activity of the androgen receptor using the repressed transactivator yeast two-hybrid system.
Wafa LA; Cheng H; Rao MA; Nelson CC; Cox M; Hirst M; Sadowski I; Rennie PS
Biochem J; 2003 Oct; 375(Pt 2):373-83. PubMed ID: 12864730
[TBL] [Abstract][Full Text] [Related]
12. Activation of two mutant androgen receptors from human prostatic carcinoma by adrenal androgens and metabolic derivatives of testosterone.
Culig Z; Stober J; Gast A; Peterziel H; Hobisch A; Radmayr C; Hittmair A; Bartsch G; Cato AC; Klocker H
Cancer Detect Prev; 1996; 20(1):68-75. PubMed ID: 8907206
[TBL] [Abstract][Full Text] [Related]
13. The inhibitory activity of a transdominant c-jun mutant fused to the ligand binding domain of the estrogen receptor.
Kim S; Brown PH; Birrer MJ
Oncogene; 1996 Mar; 12(5):1043-53. PubMed ID: 8649795
[TBL] [Abstract][Full Text] [Related]
14. Foxa1 and Foxa2 interact with the androgen receptor to regulate prostate and epididymal genes differentially.
Yu X; Gupta A; Wang Y; Suzuki K; Mirosevich J; Orgebin-Crist MC; Matusik RJ
Ann N Y Acad Sci; 2005 Dec; 1061():77-93. PubMed ID: 16467259
[TBL] [Abstract][Full Text] [Related]
15. Loss of glucocorticoid-dependent growth inhibition in transformed mouse lung cells.
Li J; Johnson TA; Hanson LA; Beer DG
Mol Carcinog; 1996 Aug; 16(4):213-20. PubMed ID: 8784464
[TBL] [Abstract][Full Text] [Related]
16. Control of the tissue inhibitor of metalloproteinases-1 promoter in culture-activated rat hepatic stellate cells: regulation by activator protein-1 DNA binding proteins.
Bahr MJ; Vincent KJ; Arthur MJ; Fowler AV; Smart DE; Wright MC; Clark IM; Benyon RC; Iredale JP; Mann DA
Hepatology; 1999 Mar; 29(3):839-48. PubMed ID: 10051488
[TBL] [Abstract][Full Text] [Related]
17. Collocation of androgen receptor gene mutations in prostate cancer.
Buchanan G; Greenberg NM; Scher HI; Harris JM; Marshall VR; Tilley WD
Clin Cancer Res; 2001 May; 7(5):1273-81. PubMed ID: 11350894
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological uncoupling of androgen receptor-mediated prostate cancer cell proliferation and prostate-specific antigen secretion.
Sathya G; Chang CY; Kazmin D; Cook CE; McDonnell DP
Cancer Res; 2003 Nov; 63(22):8029-36. PubMed ID: 14633736
[TBL] [Abstract][Full Text] [Related]
19. Expression of dominant negative Jun inhibits elevated AP-1 and NF-kappaB transactivation and suppresses anchorage independent growth of HPV immortalized human keratinocytes.
Li JJ; Rhim JS; Schlegel R; Vousden KH; Colburn NH
Oncogene; 1998 May; 16(21):2711-21. PubMed ID: 9652737
[TBL] [Abstract][Full Text] [Related]
20. Selective role of an NH2-terminal WxxLF motif for aberrant androgen receptor activation in androgen depletion independent prostate cancer cells.
Dehm SM; Regan KM; Schmidt LJ; Tindall DJ
Cancer Res; 2007 Oct; 67(20):10067-77. PubMed ID: 17942941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
